HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), March 3-6, 2014, in Boston.
Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.
HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.
Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.
A combination of 2 direct-acting antivirals developed by Bristol-Myers Squibb (BMS), daclatasvir and asunaprevir, cured 90% of previously untreated people with genotype 1b hepatitis C in 24 weeks, without the need for pegylated interferon or ribavirin, Michael Manns of Hannover Medical School reported at the 49thEASL International Liver Congress (EASL 2014) in London last week.